AVP-923-45

DRUG2 trials

Sponsors

Avanir Pharmaceuticals

Conditions

Central Neuropathic PainDyskinesiaMultiple SclerosisParkinson's Disease

Phase 2

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

CompletedNCT01324232

Avanir PharmaceuticalsCentral Neuropathic Pain, Multiple Sclerosis

Start: 2011-09-08End: 2013-09-26Updated: 2021-11-22

Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients

CompletedNCT01767129

Avanir PharmaceuticalsDyskinesia, Parkinson's Disease

Start: 2013-10-16End: 2015-02-05Updated: 2022-04-29

Related Papers

Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.

2017-03-3033 citations